How Kodiak Sciences Stock Rises To $120?

Kodiak Sciences’ stock (NASDAQ: KOD) saw a massive 75% breakout yesterday, March 26 2026, pushing the stock to nearly $40 level and expanding its market cap to $2.4 billion. This stellar run was driven by a solid Phase 3 GLOW2 data for Zenkuda (tarcocimab), an investigational therapy to treat retinal vascular diseases.

What stands out for this therapy?

1. Efficacy: 62.5% of patients achieved a ≥2-step disease improvement vs. 3.3% on placebo (p<0.0001)

2. Safety: 0% incidence of intraocular inflammation (IOI)

3. Prevention: 85% reduction in sight-threatening complications

4. Convenience: Proven 6-month dosing intervals vs the standard 4 to 8 week injection cycles required by market leaders Eylea and Vabysmo

5. Real-World Durability: Efficacy remained consistently high even for patients actively using GLP-1 medications.

Let’s unpack what this clinical win means for Kodiak’s commercial wedge, the math behind its current valuation disconnect, and the sequential roadmap that could dictate the stock’s next move.

The anti-VEGF space is a $14.5B market, per Grand View Research, with Diabetic Retinopathy (DR) representing a $10B segment on its own.

At a $2.4 billion market cap against an estimated peak sales of $1.5 billion in 2030, KOD stock is trading at a 1.6x forward peak sales multiple. High growth biotechs approaching the commercial launch of a blockbuster drug can command multiples between 8x and 10x.

The market currently values Kodiak as a clinical-stage gamble rather than a de-risked, BLA-ready commercial player. This re-rating will likely happen post DAYBREAK readout. But, even if we apply a conservative 5x multiple, standard for established pharma companies nearing major regulatory approval, would imply a $7.5 billion valuation. This represents a 3x upside, pushing the stock past $120 per share. Of course, this won’t happen overnight.

Such re-rates periodically happen across industries as the market recognizes developing moat and long-term compounding ability. Here is another potential stock that could re-rate as it captures the AI Backbone: Marvell’s AI Edge: 30% Growth at 26x Earnings

The stock’s ascent to a commercial multiple will happen sequentially based on three upcoming milestones:

1. Q3 2026 (The DAYBREAK Readout): Phase 3 data for wet AMD. This is an optionality play. A win adds a second multi-billion-dollar indication and will force immediate analyst upgrades. A miss trims the upside but leaves the Diabetic Retinopathy baseline intact.

2. Late 2026 (BLA Submission): The formal FDA filing for Zenkuda. This fundamentally de-risks the asset, lowering the discount rate applied to future cash flows.

3. 2027 (FDA Approval & Launch): The final re-rate. KOD stops trading on trial anxiety and starts trading on revenue visibility.

The Balance Sheet: KOD ended Q3 2025 with $72 million in cash while burning $61.5 million (though it includes $14 million in stock based compensation). A dilutive equity raise is likely before commercial revenues arrive. On December 18, 2025, Kodiak Sciences completed a $184 million public offering of common stock. This upsized financing provides the necessary runway to support the company’s Phase 3 retina program well into 2027. But it may need more funds for the commercial launch.

The Launch Mechanics: Kodiak currently has no salesforce. Fighting Regeneron and Roche for market share requires either massive capital expenditure or a major pharma partnership.

FDA and Trial Risk: While GLOW2 was clean, any unexpected safety signal during the FDA review will likely be catastrophic. A miss on DAYBREAK in Q3 won’t kill the company, but it could trigger a painful correction.

The clinical data supports a significantly higher valuation, but the climb will test investor patience. Zenkuda has the efficacy, safety, and dosing profile to carve out a massive wedge in a $15B market, but Kodiak must first navigate a highly restrictive balance sheet to reach the finish line.

While the math points to a massive valuation re-rate potential for Kodiak, clinical-stage biotech remains a “binary” arena where even stellar data can be sidelined by regulatory technicalities or balance-sheet constraints. The potential for outsized returns is undeniable, but the inherent volatility of single-drug bets can be catastrophic for a concentrated portfolio. A more resilient strategy involves a disciplined, data-backed approach that diversifies risk across high-quality assets in multiple sectors. This is the foundation of the Trefis High Quality (HQ) Portfolio, which has delivered over 105% returns since inception by capturing alpha while neutralizing sector-specific shocks. Discover the full HQ performance metrics and the 5 data-backed reasons why it outperformed.